Cingulate Inc. Share Price & Technical Analysis
CING · $4.76 (+6.49%)
Healthcare / Biotechnology
$4.76
+6.49%
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It a…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-13% return in May, -17% avg return in past 3 year May month.
14% return in 2026, -75% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 33% | 11% | 2% | -17% | -13% | – | – | – | – | – | – | – | 14% |
| 25 | -8% | -7% | 2% | -5% | -9% | 5% | 27% | -22% | -2% | -3% | 0% | 19% | -2% |
| 24 | -56% | -56% | -17% | -17% | -27% | -56% | -5% | 88% | -31% | -20% | 13% | 9% | -175% |
| 23 | -7% | 79% | -45% | 5% | -15% | 0% | -42% | 15% | 8% | -37% | -29% | 19% | -48% |
| 22 | -32% | -21% | 37% | -16% | -30% | 31% | -14% | 33% | -34% | -9% | -11% | -1% | -65% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$58.50M
P/E ratio
—
52W high
$11.89
52W low
$3.20
Volume
7,71,259
Beta
-0.81
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cingulate Inc. share price today?
- Cingulate Inc. (CING) last traded around $4.76 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CING have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CING. Download the app for real-time alerts.
- How can I analyze Cingulate Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.